Gene:
ARRB1
arrestin, beta 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  arrestin 2
Alternate Symbols:  None
PharmGKB Accession Id: PA59

Details

Cytogenetic Location: chr11 : q13.4 - q13.4
GP mRNA Boundary: chr11 : 74971166 - 75062875
GP Gene Boundary: chr11 : 74968166 - 75072875
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Information ?

No related diseases are available

Publications related to ARRB1: 7

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics. 2011. Morag Ayelet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta-arrestins 1 and 2 are associated with nicotine dependence in European American smokers. Molecular psychiatry. 2008. Sun D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cellular signalling. 2003. Penela Petronila, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. The Biochemical journal. 2003. Shenoy Sudha K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. The Journal of biological chemistry. 2003. Shenoy Sudha K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (New York, N.Y.). 2002. Perry Stephen J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Progress in neurobiology. 2002. Claing Audrey, et al. PubMed

LinkOuts

Entrez Gene:
408
OMIM:
107940
UCSC Genome Browser:
NM_004041
RefSeq RNA:
NM_004041
NM_020251
RefSeq Protein:
NP_004032
NP_064647
RefSeq DNA:
AC_000054
AC_000143
NC_000011
NT_167190
NW_001838028
NW_925106
UniProtKB:
ARRB1_HUMAN (P49407)
Ensembl:
ENSG00000137486
GenAtlas:
ARRB1
GeneCard:
ARRB1
MutDB:
ARRB1
ALFRED:
LO060727W
HuGE:
ARRB1
Comparative Toxicogenomics Database:
408
ModBase:
P49407
HumanCyc Gene:
HS06346
HGNC:
711

Common Searches